MannKind (MNKD) 주식 개요
만카인드 코퍼레이션은 바이오 제약 회사로 만성 질환 치료를 혁신하기 위한 다양한 솔루션을 제공하는 데 주력하고 있습니다. 자세히 보기
MNKD Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
MannKind Corporation 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$3.75 |
| 52주 최고가 | US$6.51 |
| 52주 최저가 | US$2.23 |
| 베타 | 1.1 |
| 1개월 변동 | -2.60% |
| 3개월 변동 | -6.25% |
| 1년 변동 | -32.68% |
| 3년 변동 | -13.79% |
| 5년 변동 | -17.22% |
| IPO 이후 변동 | -94.67% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Aug 17
MNKD: Upcoming Autoinjector Decision Will Reframe Perceived Royalty Risk
Analysts have raised their fair value estimate for MannKind from $11.00 to approximately $12.74, citing a higher Street price target of $14 that is tied to Furoscix and MNKD-201 expectations, as well as increased attention on the upcoming Furoscix ReadyFlow Autoinjector FDA decision. Analyst Commentary Recent commentary from bullish analysts on MannKind centers on rising confidence in the Furoscix franchise and the MNKD-201 program.Seeking Alpha • Aug 13
MannKind: New Approvals Majorly Increase MannKind's Prospects
Summary Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years. While I rate MNKD a " Strong Buy" based upon its FDA approvals, it still has significant risks of execution. Read the full article on Seeking Alpha내러티브 업데이트 • Aug 03
MNKD: Furoscix Autoinjector Approval Will Reset Perceived Royalty Risk
Analysts have lifted their price target on MannKind to $14 from $11, citing higher expectations for Furoscix and the '201 program, along with updated assumptions around tissue exposure and potential Phase 2 read-throughs. Analyst Commentary Recent research coverage around MannKind highlights growing confidence in the company’s pipeline and product execution, particularly around Furoscix and the '201 program.Recent updates
내러티브 업데이트 • Aug 17
MNKD: Upcoming Autoinjector Decision Will Reframe Perceived Royalty Risk
Analysts have raised their fair value estimate for MannKind from $11.00 to approximately $12.74, citing a higher Street price target of $14 that is tied to Furoscix and MNKD-201 expectations, as well as increased attention on the upcoming Furoscix ReadyFlow Autoinjector FDA decision. Analyst Commentary Recent commentary from bullish analysts on MannKind centers on rising confidence in the Furoscix franchise and the MNKD-201 program.Seeking Alpha • Aug 13
MannKind: New Approvals Majorly Increase MannKind's Prospects
Summary Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years. While I rate MNKD a " Strong Buy" based upon its FDA approvals, it still has significant risks of execution. Read the full article on Seeking Alpha내러티브 업데이트 • Aug 03
MNKD: Furoscix Autoinjector Approval Will Reset Perceived Royalty Risk
Analysts have lifted their price target on MannKind to $14 from $11, citing higher expectations for Furoscix and the '201 program, along with updated assumptions around tissue exposure and potential Phase 2 read-throughs. Analyst Commentary Recent research coverage around MannKind highlights growing confidence in the company’s pipeline and product execution, particularly around Furoscix and the '201 program.
내러티브 업데이트 • Jun 22
MNKD: Pediatric Insulin Approval Will Test Commercial Execution And Reprice Future Upside
The latest narrative update on MannKind reflects a higher analyst price target, moving from $7.17 to $7.59, as analysts highlight Afrezza's pediatric approval while still viewing the company as a "show me" story on commercial execution. Analyst Commentary Recent research on MannKind centers on how Afrezza's pediatric approval could affect the company's long term commercial story, while mixed target moves show differing views on execution risk and valuation.내러티브 업데이트 • Jun 05
MNKD: Pediatric Approval And Trial Progress Will Reset Perceived Royalty Risk
Analysts have raised their MannKind price target to $11 from $8. This reflects updated assumptions that include Afrezza's pediatric approval, a lower discount rate, and higher expected profit margins, even as projected revenue growth and future P/E move slightly lower.
내러티브 업데이트 • May 21
MNKD: 2026 Pediatric Decision Will Shape Royalty Overhang And Rebound Potential
Analysts have updated their view on MannKind with a new fair value estimate of $4.75 per share, reflecting recent shifts in price targets as they balance concerns about Tyvaso DPI royalty risk against ongoing contributions from products like Furoscix and Afrezza. Analyst Commentary Recent research highlights a split in how professionals are valuing MannKind, with much of the debate centered on the durability of Tyvaso DPI royalties and how that uncertainty should be reflected in the share price.내러티브 업데이트 • May 04
MNKD: Soft Mist Inhaler Risk Seen Resetting Future Royalty Upside
Narrative Update Analysts have trimmed their average price target on MannKind to about $8. This reflects updated assumptions for higher revenue growth but lower profit margins and a more moderate future P/E as they weigh potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans.내러티브 업데이트 • Apr 20
MNKD: 2026 Pediatric Insulin Decision Will Reset Treprostinil Royalty Risk
Analysts have trimmed MannKind's average price target by about $0.33, reflecting slightly lower assumptions for fair value and profitability as they factor in potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans, even though some still see opportunity in the broader portfolio. Analyst Commentary Recent research has become more cautious on MannKind, with several firms trimming price targets and one moving to a more neutral rating as they reassess the risk and reward around Tyvaso DPI royalties and the impact of United Therapeutics' soft mist inhaler plans.내러티브 업데이트 • Apr 06
MNKD: 2026 Pediatric Decision Will Define Royalty Overhang And Bullish Setup
Narrative Update: MannKind MannKind's updated analyst price target has been reduced from about $7.50 to roughly $3.85, as analysts factor in softer modeled revenue growth, a higher discount rate, lower assumed future P/E and rising concerns that United Therapeutics' planned soft mist inhaler could weigh on the long term value of Tyvaso DPI royalties. Some still highlight potential support from Afrezza and Furoscix and argue the recent selloff may already reflect a worst case scenario.내러티브 업데이트 • Mar 22
MNKD: 2026 Afrezza FDA Decisions Will Recast Treprostinil Royalty Risk
Analysts have trimmed their average price targets on MannKind by a few dollars into the mid single digit range, reflecting fresh concerns about long term Tyvaso DPI royalties as United Therapeutics pursues a soft mist inhaler, while still recognizing potential support from Furoscix and Afrezza. Analyst Commentary Recent Street commentary on MannKind highlights a split view, with many price targets pulled into a mid single digit to low double digit range as analysts weigh Tyvaso DPI royalty risk against potential contributions from Afrezza and Furoscix, as well as MannKind's broader pipeline.내러티브 업데이트 • Mar 08
MNKD: 2026 FDA Decisions On Inhaled Insulin Will Reframe Royalty Risk
Analysts have trimmed their fair value view on MannKind to $7.50 from $9.61, citing lower price targets clustered around $3.50 to $11 as they factor in softer revenue growth and profit margin assumptions, as well as higher perceived risk tied to United Therapeutics' potential soft mist inhaler competition and the timing of Tyvaso DPI royalty data. Analyst Commentary Recent Street research on MannKind reflects a wide split in opinion, with some analysts focusing on potential upside from the broader product portfolio and others emphasizing new competitive risks to Tyvaso DPI royalties and collaboration revenue.내러티브 업데이트 • Feb 22
MNKD: 2026 FDA Label And Pediatric Decisions Will Drive Bullish Case
Analysts have kept their fair value estimate for MannKind steady while refining key inputs like discount rate, revenue growth, profit margin and future P/E. They link their current price targets, including one at $11, to what they see as multiple potential tailwinds tied to upcoming FDA decisions on Afrezza in 2026.내러티브 업데이트 • Feb 07
MNKD: Upcoming FDA Decisions In 2026 Will Define Upside Potential
Narrative Update on MannKind Analysts have trimmed their price target on MannKind from $8.00 to $7.50, balancing reduced fair value and margin assumptions with expectations for stronger revenue growth. They also recognize that recent Street research still highlights potential tailwinds tied to upcoming FDA decisions and the updated pipeline outlook.내러티브 업데이트 • Jan 23
MNKD: 2026 FDA Label Decisions Will Clarify Underappreciated Upside Potential
Narrative Update on MannKind The analyst price target for MannKind has been reset to $10, reflecting updated views after one firm removed MNKD-101/NTM from its valuation while others highlight potential upside tied to upcoming FDA decisions and what they see as underappreciated tailwinds into 2026. Analyst Commentary Recent research on MannKind reflects a mix of optimism around upcoming FDA decisions and caution after the removal of MNKD-101/NTM from valuation models.내러티브 업데이트 • Jan 09
MNKD: 2026 Regulatory Decisions Will Drive Reassessment Of Future Prospects
Narrative Update: MannKind Analyst Price Target Shift Analysts have reset their price targets on MannKind into a tighter US$10 to US$11 range, reflecting a mix of reduced expectations after the discontinuation of MNKD-101/NTM and continued optimism around potential 2026 tailwinds that are not yet fully reflected in the shares. Analyst Commentary Recent research views on MannKind reflect both optimism around potential 2026 catalysts and caution following pipeline changes and trial outcomes.내러티브 업데이트 • Dec 23
MNKD: Future Commercial Execution Will Offset Late Stage Pipeline Disappointment
Analysts have trimmed their price target on MannKind to approximately $10 per share, a modest reduction that reflects the removal of MNKD-101/NTM from valuation assumptions, while improved revenue growth and profit margin forecasts partially offset the impact. Analyst Commentary Analyst reactions to the updated price target highlight a mixed outlook, with optimism around MannKind's core commercial performance tempered by concern over the setback in its development pipeline.내러티브 업데이트 • Dec 09
MNKD: Future Commercial Portfolio Will Offset Pipeline Setback Risk
Analysts have reduced their price target on MannKind from $15.00 to $10.00 per share, citing the removal of MNKD-101/NTM from the pipeline following the discontinuation of the Phase 3 ICoN-1 trial after a futility assessment. Analyst Commentary Analysts view the updated price target as a recalibration of MannKind's valuation to reflect the loss of MNKD-101/NTM from the development pipeline, while still recognizing ongoing strengths in the core business and broader platform.내러티브 업데이트 • Nov 25
MNKD: Recent Pipeline Setback Will Be Outweighed By Future Royalties Expansion
Analysts have reduced their price target for MannKind from approximately $10.06 to $9.39, citing the discontinued Phase 3 ICoN-1 trial and adjusted pipeline expectations as the main factors for the revision. Analyst Commentary Analyst sentiment on MannKind has shifted in response to recent clinical trial results, pipeline updates, and royalty projections.내러티브 업데이트 • Nov 11
MNKD: Acquisition Will Drive Revenue Diversification and Support Upside Re-Rating
MannKind's fair value estimate has been revised down slightly to $10.06 per share from $10.57. Analysts are factoring in stronger revenue growth driven by TYVASO DPI royalties and the accretive acquisition of scPharmaceuticals, along with a modest change in profitability and updated discount rates.분석 기사 • Sep 03
MannKind Corporation (NASDAQ:MNKD) Looks Just Right With A 53% Price Jump
MannKind Corporation ( NASDAQ:MNKD ) shareholders would be excited to see that the share price has had a great month...내러티브 업데이트 • Aug 27
Pipeline Advancements And International Expansion Will Shape Future Markets
Analysts have raised MannKind’s price target to $9.71, citing the accretive acquisition of scPharmaceuticals, which expands and diversifies MannKind’s addressable market and growth prospects despite recent negative sentiment around earnings. Analyst Commentary Bullish analysts see the acquisition of scPharmaceuticals as adding a high-growth, large-market asset that diversifies MannKind's revenue base.분석 기사 • May 11
Earnings Miss: MannKind Corporation Missed EPS By 5.9% And Analysts Are Revising Their Forecasts
Shareholders might have noticed that MannKind Corporation ( NASDAQ:MNKD ) filed its first-quarter result this time last...분석 기사 • Mar 01
MannKind Corporation Just Missed EPS By 6.3%: Here's What Analysts Think Will Happen Next
MannKind Corporation ( NASDAQ:MNKD ) shareholders are probably feeling a little disappointed, since its shares fell...Seeking Alpha • Dec 17
MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets
Summary MannKind Corporation is a biopharmaceutical company focused on inhaled therapies for endocrine and orphan lung diseases. MNKD's revenue growth is driven by Tyvaso DPI royalties and Afrezza expansion, with pediatric trials targeting a significant underserved market. MNKD's pipeline includes MNKD-101 for nontuberculous mycobacterial lung disease and MNKD-201 for idiopathic pulmonary fibrosis, with significant market potential if successfully commercialized. The orphan lung pipeline includes MNKD-101 (Phase 3 for NTM lung disease) and MNKD-201 (Phase 1 for IPF), addressing high unmet needs. Despite high leverage, I believe MNKD's revenue growth prospects support a speculative "Buy" rating for investors seeking exposure to IPF and endocrine biotech niches. Read the full article on Seeking AlphaSeeking Alpha • Oct 03
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
Summary MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 million, largely due to Tyvaso DPI royalties and manufacturing income. MannKind is advancing a promising pipeline, including MNKD 101 and Nintedanib DPI, aimed at addressing unmet needs in orphan lung diseases. Financially, MannKind has strong liquidity but remains burdened by long-term debt obligations and modest net losses. I maintain a "buy" recommendation based on MannKind's solid revenue from Tyvaso DPI and its potential in expanding respiratory treatments. Read the full article on Seeking Alpha분석 기사 • Sep 18
MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Despite an already strong run, MannKind Corporation ( NASDAQ:MNKD ) shares have been powering on, with a gain of 28% in...
새로운 내러티브 • Sep 12
Innovative Pipeline And Decisive Deleveraging Poise Company For Explosive Growth And Profitability
Strong demand for Tyvaso DPI and advancements in pipeline drugs like clofazimine inhalation suspension highlight MannKind's successful commercial execution and promising revenue growth prospects.분석 기사 • Jul 17
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
Key Insights The projected fair value for MannKind is US$11.86 based on 2 Stage Free Cash Flow to Equity MannKind is...Seeking Alpha • May 15
MannKind Outperforms As Tyvaso DPI Captures Market Share
Summary MannKind's Q1 revenue rose 63% year-over-year; net income was $10.63 million, reversing a prior loss. Tyvaso DPI, utilizing MannKind’s technosphere technology, continues to capture significant PAH market interest. Despite high current assets, the Company's long-term liabilities exceed its assets, posing potential financial risks. Recommend buying MNKD for a barbell strategy portfolio, allocating a small portion to this high-alpha stock. Read the full article on Seeking Alpha주주 수익률
| MNKD | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | -7.6% | -5.2% | -0.9% |
| 1Y | -32.7% | 37.6% | 14.2% |
수익률 대 산업: MNKD은 지난 1년 동안 37.6%의 수익을 기록한 US Biotechs 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: MNKD은 지난 1년 동안 14.2%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| MNKD volatility | |
|---|---|
| MNKD Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
안정적인 주가: MNKD는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: MNKD의 주간 변동성(9%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1991 | 592 | Michael Castagna | mannkindcorp.com |
바이오제약 기업인 맨킨드 코퍼레이션(MannKind Corporation)은 만성 질환 치료의 패러다임을 전환하기 위한 다양한 솔루션을 제공하는 데 주력하고 있습니다. 이 회사는 당뇨병, 폐고혈압, 심부전 및 만성 신장 질환에 따른 체액 과부하 등 심각한 미충족 의료 수요를 해결하는 치료제를 개발하고 상용화하고 있습니다. 이 회사는 당뇨병 성인의 혈당 조절을 개선하는 데 사용되는 흡입형 인슐린인 ‘아프레자(Afrezza) 흡입 분말’과, 성인에게 인슐린을 지속적으로 피하 주입하는 웨어러블 인슐린 투여 기기인 ‘V-Go’를 제공하고 있습니다.
MannKind Corporation 기초 지표 요약
| MNKD 기초 통계 | |
|---|---|
| 시가총액 | US$1.21b |
| 순이익 (TTM) | -US$43.61m |
| 매출 (TTM) | US$393.63m |
3.1x
주가매출비율(P/S)-27.6x
주가수익비율(P/E)MNKD는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| MNKD 손익계산서 (TTM) | |
|---|---|
| 매출 | US$393.63m |
| 매출원가 | US$96.89m |
| 총이익 | US$296.74m |
| 기타 비용 | US$340.36m |
| 순이익 | -US$43.61m |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -0.14 |
| 총이익률 | 75.39% |
| 순이익률 | -11.08% |
| 부채/자본 비율 | -474.9% |
MNKD의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/13 06:42 |
| 종가 | 2026/09/11 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
MannKind Corporation는 27명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Thomas Russo | Baird |
| Stephen V. Byrne | BofA Global Research |
| null null | BTIG |